What Happened?
New York, NY-based MindMed Appointed Bradford Cross as Chief Technology Officer
About the Company
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
About the Person
Bradford Cross is Chief Technology Officer at MindMed. Previously, Bradford held various senior IT leadership roles in the industry.
Info Source
News
Short Profile